Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neuroendocrine Tumors

ClinicalTrials.gov lists 4,526 trials for Neuroendocrine Tumors or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 287.

MeSH D018358 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,017 Phase 1/2 Phase 1/2 538 Phase 2 Phase 2 1,321 Phase 2/3 Phase 2/3 32 Phase 3 Phase 3 235 Phase 4 Phase 4 56 Not applicable Not applicable 500 Observational Observational 786 Phase 1 Phase 1 1,017 Phase 1/2 Phase 1/2 538 Phase 2 Phase 2 1,321 Phase 2/3 Phase 2/3 32 Phase 3 Phase 3 235 Phase 4 Phase 4 56 Not applicable Not applicable 500 Observational Observational 786

Trials per phase (log scale)

1 more section with rows

538 of the 4,526 trials are tagged with Neuroendocrine Tumors itself; the rest are tagged with a narrower condition beneath it.

Get the Neuroendocrine Tumors report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neuroendocrine Tumors trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 281

1990: 2 trials (Observational 2) 1991: 5 trials (Observational 3, Not applicable 1, Phase 2 1) 1992: 4 trials (Observational 1, Not applicable 2, Phase 3 1) 1993: 4 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 1) 1994: 3 trials (Phase 2 1, Phase 1 2) 1995: 11 trials (Observational 2, Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 2) 1996: 17 trials (Observational 4, Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 4) 1997: 19 trials (Observational 4, Phase 3 1, Phase 2 5, Phase 1/2 4, Phase 1 5) 1998: 30 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 17, Phase 1/2 2, Phase 1 5) 1999: 53 trials (Observational 7, Phase 3 6, Phase 2 25, Phase 1/2 4, Phase 1 11) 2000: 50 trials (Observational 9, Not applicable 5, Phase 3 5, Phase 2 11, Phase 1/2 5, Phase 1 15) 2001: 51 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 20, Phase 1/2 6, Phase 1 16) 2002: 53 trials (Observational 5, Not applicable 3, Phase 3 7, Phase 2 18, Phase 1/2 10, Phase 1 10) 2003: 65 trials (Observational 8, Not applicable 5, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 30, Phase 1/2 8, Phase 1 8) 2004: 92 trials (Observational 7, Not applicable 6, Phase 3 4, Phase 2/3 1, Phase 2 44, Phase 1/2 10, Phase 1 20) 2005: 106 trials (Observational 9, Not applicable 7, Phase 3 6, Phase 2/3 2, Phase 2 47, Phase 1/2 13, Phase 1 22) 2006: 113 trials (Observational 11, Not applicable 3, Phase 4 1, Phase 3 7, Phase 2 47, Phase 1/2 15, Phase 1 29) 2007: 107 trials (Observational 14, Not applicable 6, Phase 4 2, Phase 3 7, Phase 2 44, Phase 1/2 12, Phase 1 22) 2008: 124 trials (Observational 28, Not applicable 5, Phase 4 1, Phase 3 6, Phase 2 44, Phase 1/2 8, Phase 1 32) 2009: 125 trials (Other 1, Observational 18, Not applicable 11, Phase 3 7, Phase 2/3 2, Phase 2 44, Phase 1/2 13, Phase 1 29) 2010: 139 trials (Observational 16, Not applicable 5, Phase 4 1, Phase 3 7, Phase 2 54, Phase 1/2 19, Phase 1 37) 2011: 143 trials (Observational 20, Not applicable 14, Phase 4 3, Phase 3 7, Phase 2/3 3, Phase 2 50, Phase 1/2 8, Phase 1 38) 2012: 149 trials (Observational 21, Not applicable 18, Phase 4 3, Phase 3 9, Phase 2 45, Phase 1/2 16, Phase 1 37) 2013: 185 trials (Observational 33, Not applicable 20, Phase 4 5, Phase 3 10, Phase 2 57, Phase 1/2 12, Phase 1 48) 2014: 182 trials (Observational 26, Not applicable 20, Phase 4 3, Phase 3 8, Phase 2 62, Phase 1/2 24, Phase 1 39) 2015: 225 trials (Other 1, Observational 31, Not applicable 29, Phase 4 7, Phase 3 12, Phase 2/3 2, Phase 2 62, Phase 1/2 30, Phase 1 51) 2016: 196 trials (Observational 36, Not applicable 22, Phase 4 2, Phase 3 9, Phase 2 44, Phase 1/2 25, Phase 1 58) 2017: 226 trials (Observational 40, Not applicable 27, Phase 4 3, Phase 3 11, Phase 2/3 2, Phase 2 66, Phase 1/2 30, Phase 1 47) 2018: 216 trials (Observational 41, Not applicable 28, Phase 4 2, Phase 3 9, Phase 2/3 3, Phase 2 47, Phase 1/2 33, Phase 1 53) 2019: 227 trials (Observational 50, Not applicable 34, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 56, Phase 1/2 28, Phase 1 48) 2020: 228 trials (Observational 45, Not applicable 28, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 57, Phase 1/2 32, Phase 1 58) 2021: 281 trials (Observational 56, Not applicable 42, Phase 4 2, Phase 3 8, Phase 2/3 2, Phase 2 79, Phase 1/2 34, Phase 1 58) 2022: 247 trials (Observational 53, Not applicable 33, Phase 4 2, Phase 3 15, Phase 2/3 1, Phase 2 53, Phase 1/2 27, Phase 1 63) 2023: 206 trials (Observational 45, Not applicable 28, Phase 4 3, Phase 3 15, Phase 2/3 3, Phase 2 46, Phase 1/2 31, Phase 1 35) 2024: 190 trials (Observational 57, Not applicable 30, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 37, Phase 1/2 22, Phase 1 34) 2025: 210 trials (Observational 48, Not applicable 30, Phase 4 4, Phase 3 9, Phase 2/3 5, Phase 2 41, Phase 1/2 29, Phase 1 44)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 166
2025 210
2024 190
2023 206
2022 247
2021 281
2020 228
2019 227
2018 216
2017 226

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 180 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 510 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 2,781 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neuroendocrine Tumors trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,017
Phase 1/2 538
Phase 2 1,321
Phase 2/3 32
Phase 3 235
Phase 4 56
Not applicable 500
Observational 786
Expanded access 41

How many Neuroendocrine Tumors trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 128
Recruiting 616
Enrolling by invitation 24
Active, not recruiting 371
Available 8

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neuroendocrine Tumors trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 287
Bristol-Myers Squibb 90
Novartis Pharmaceuticals 70
Hoffmann-La Roche 48
Pfizer 42

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Neuroendocrine Tumors? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 285
NIVOLUMAB 253
IPILIMUMAB 235
Cytoxan 134
GSK1120212 77

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Low-dose Aldesleukin (Proleukin®) 109
SQ Fludarabine 95
SOC: Temozolomide 84
Vermurafenib 64
Arm 3: Dacarbazine 64

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neuroendocrine Tumors trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malignant neoplasm progression 2,036 66
Pyrexia 1,662 203
Pneumonia 1,450 217
Fatigue 1,164 226
Vomiting 1,074 282

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neuroendocrine Tumors? (550)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Assessment of the diagnostic efficacy and clinical significance of [<sup>18</sup>F]AlF-NOTA-LM3 PET/CT in patients with well-differentiated neuroendocrine tumors. European journal of nuclear medicine and molecular imaging 2026 Yes
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Endocrine-related cancer 2026 Yes
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p). European journal of cancer (Oxford, England : 1990) 2025 Yes
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. The New England journal of medicine 2025 Yes
Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial]. European journal of nuclear medicine and molecular imaging 2025 Yes

Showing 5 of 550 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (15)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Neuroendocrine neoplasm Point prevalence 1-5 / 10 000 United States US Unspecified
Neuroendocrine neoplasm Annual incidence 1-9 / 100 000 United States US Exact
Neuroendocrine neoplasm Point prevalence 1-5 / 10 000 United States US Exact
Neuroendocrine neoplasm Annual incidence 1-9 / 100 000 United States US Unspecified
Neuroendocrine neoplasm Annual incidence 1-9 / 100 000 United States US Exact

Showing 5 of 15 prevalence observations.

Start your 14-day trial Email me all 15 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Neuroendocrine neoplasm 877 Exact Orphadata Science knowledge files, Product 1
Neuroendocrine neoplasm 877 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages